Back to Archived Journals » Orphan Drugs: Research and Reviews » Volume 1

Medical treatment of rare diseases must be put on the agenda

Authors Aagaard L

Published 23 September 2011 Volume 2011:1 Pages 1—2

DOI https://doi.org/10.2147/ODRR.S25714


Lise Aagaard
Faculty of Pharmaceutical Sciences, University of Copenhagen, University of Copenhagen, Copenhagen, Denmark

The development of medicines for the treatment of rare diseases is important to many, including both patients and prescribers, but has traditionally been of minor interest to the pharmaceutical industry due to the often low number of patients with a rare disease. Politicians and regulators have recently acknowledged this problem, and favorable licensing conditions are now offered to pharmaceutical companies developing new medications for rare diseases to make these products more accessible.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]